{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:54:25Z","timestamp":1784159665192,"version":"3.55.0"},"reference-count":31,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Clinical Therapy Research in the Specialist Health Services","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,6,1]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>In the multisystem inflammatory disorder systemic sclerosis (SSc), gastrointestinal tract (GIT) affliction is highly prevalent. There are no known disease modifying therapies and the negative impact is substantial. Aiming for a new therapeutic principle, and inspired by recent work showing associations between gut microbiota changes and GIT symptoms in SSc, we performed a pilot study on faecal microbiota transplantation (FMT) with the single-donor bacterial culture \u2018Anaerobic Cultivated Human Intestinal Microbiome (ACHIM)\u2019. Motivated by positive pilot study signals, we designed the ReSScue trial as a phase II multicentre, placebo-controlled, randomised 20-week trial to evaluate safety and efficacy on lower GIT symptoms of FMT by ACHIM in SSc.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analyses<\/jats:title>\n                  <jats:p>We aim to include 70 SSc participants with moderate to severe lower GIT symptoms, defined by the validated patient-reported University of California Los Angeles Scleroderma Clinical Trial Consortium GIT 2.0 2.0 questionnaire. The trial includes three parts. In part A1 (induction phase) lasting from week 0 to week 12, participants will be randomised 1:1 to repeat infusions of 30 mL ACHIM or placebo at week 0 and 2 by gastroduodenoscopy. In part A2, which is an 8-week subsequent maintenance phase, all study participants will receive 30 mL ACHIM at week 12 and followed until week 20 on continued blind. In part B, which will last until the last participant completes part A2, the participants will be followed through a maximum 16-week extended monitoring period, for longer-term data on safety and intervention effects. Primary endpoint is change from baseline to week 12 in UCLA GIT subscale scores of diarrhoea or bloating, depending on the worst symptom at baseline evaluated separately for each patient. Secondary endpoints are safety measures and changes in UCLA GIT scores (total, diarrhoea and bloating).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>This protocol was approved by the Northern Norwegian Committee for Medical Ethics. Study findings will be published.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04300426\">NCT04300426<\/jats:ext-link>; Pre-results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Protocol version<\/jats:title>\n                  <jats:p>V.3.1.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-048541","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T12:25:59Z","timestamp":1624537559000},"page":"e048541","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04300426","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-7422","authenticated-orcid":false,"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5vard H","family":"Fretheim","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas K","family":"Sarna","sequence":"additional","affiliation":[{"name":"Department of gastroenterology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imon","family":"Barua","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maylen N","family":"Carstens","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-4453","authenticated-orcid":false,"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R","family":"Volkmann","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"Midtvedt","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Didriksen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvilde","family":"Dhainaut","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St Olavs Hospital Universitetssykehuset i Trondheim, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Kristine","family":"Halse","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Bergen, Bergen, Hordaland, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnstein","family":"Bakland","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of North Norway, Tromso, Troms, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiju","family":"Pesonen","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics & Epidemiology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Olsen","sequence":"additional","affiliation":[{"name":"Oslo Centre for Biostatistics & Epidemiology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"Molberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital, Oslo, Norway"},{"name":"Faculty of medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"2025101811593724000_11.6.e048541.1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"The Lancet"},{"key":"2025101811593724000_11.6.e048541.2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semarthrit.2016.02.005","article-title":"Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey","volume":"46","author":"Frantz","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025101811593724000_11.6.e048541.3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2397198319891282","article-title":"Gastrointestinal involvement in systemic sclerosis: effects on morbidity and mortality and new therapeutic approaches","volume":"6","author":"Hoffmann-Vold","year":"2021","journal-title":"Journal of Scleroderma and Related Disorders"},{"key":"2025101811593724000_11.6.e048541.4","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1093\/rheumatology\/keaa026","article-title":"Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort","volume":"59","author":"Fretheim","year":"2020","journal-title":"Rheumatology"},{"key":"2025101811593724000_11.6.e048541.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217035"},{"key":"2025101811593724000_11.6.e048541.6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5301\/jsrd.5000214","article-title":"Gastrointestinal manifestations of systemic sclerosis","volume":"1","author":"Shreiner","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"2025101811593724000_11.6.e048541.7","article-title":"Consensus best practice pathway of the UK scleroderma Study group: gastrointestinal manifestations of systemic sclerosis","volume":"32(6 Suppl 86)","author":"Hansi","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2025101811593724000_11.6.e048541.8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/art.39572","article-title":"Systemic sclerosis is associated with a unique colonic microbial consortium","volume":"68","author":"Volkmann","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025101811593724000_11.6.e048541.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2017-000134"},{"key":"2025101811593724000_11.6.e048541.10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5152\/eurjrheum.2019.19103","article-title":"Gastrointestinal tract microbiota modifications in systemic sclerosis","volume":"7","author":"Volkmann","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"2025101811593724000_11.6.e048541.11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev-med-111717-122956","article-title":"Clinical application and potential of fecal microbiota transplantation","volume":"70","author":"Ooijevaar","year":"2019","journal-title":"Annu Rev Med"},{"key":"2025101811593724000_11.6.e048541.12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/1744666X.2019.1707665","article-title":"The potential of fecal microbiota transplantation in systemic sclerosis","volume":"16","author":"Hoffmann-Vold","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2025101811593724000_11.6.e048541.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205037"},{"key":"2025101811593724000_11.6.e048541.14","doi-asserted-by":"crossref","first-page":"101607","DOI":"10.1016\/j.bpg.2019.03.003","article-title":"Therapeutic potential of an anaerobic cultured human intestinal microbiota, ACHIM, for treatment of IBS","volume":"40-41","author":"Benno","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2025101811593724000_11.6.e048541.15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/1744666X.2019.1656528","article-title":"Just another crappy commentary: the future of fecal microbiota transplantation","volume":"15","author":"Rosenbaum","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2025101811593724000_11.6.e048541.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-017-0687-5","article-title":"Faecal microbiota transplantation: a regulatory hurdle?","volume":"17","author":"Verbeke","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"2025101811593724000_11.6.e048541.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910437"},{"key":"2025101811593724000_11.6.e048541.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1803103"},{"key":"2025101811593724000_11.6.e048541.19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S2468-1253(20)30082-0","article-title":"Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel","volume":"5","author":"Ianiro","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025101811593724000_11.6.e048541.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232739","article-title":"Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial","volume":"15","author":"Fretheim","year":"2020","journal-title":"PLoS One"},{"key":"2025101811593724000_11.6.e048541.21","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000434668.32150.e5"},{"key":"2025101811593724000_11.6.e048541.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.24730"},{"key":"2025101811593724000_11.6.e048541.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110225"},{"key":"2025101811593724000_11.6.e048541.24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(17)30338-2","article-title":"Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial","volume":"3","author":"Johnsen","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025101811593724000_11.6.e048541.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5145"},{"key":"2025101811593724000_11.6.e048541.26","first-page":"75","article-title":"Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS\u2122)","volume":"35(Suppl 106)","author":"Distler","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2025101811593724000_11.6.e048541.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2025101811593724000_11.6.e048541.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2025101811593724000_11.6.e048541.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.17077"},{"key":"2025101811593724000_11.6.e048541.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2015.05.014"},{"key":"2025101811593724000_11.6.e048541.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-048541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:59:46Z","timestamp":1760813986000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-048541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,24]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bmjopen-2020-048541"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-048541","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}